Ivabradine Aspire (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. Inhibition of this current slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate without affecting contractility, blood pressure, or ventricular repolarisation.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any titration schedule according to current clinical guidelines.

Safety of ivabradine during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To request Ivabradine Aspire, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine is often added when beta‑blockers alone do not achieve target heart‑rate control.

Store Ivabradine Aspire at room temperature, below 25 °C, in the original blister pack or container. Protect the tablets from moisture, excessive heat and direct sunlight. Do not store in a refrigerator or freezer, and keep out of reach of children.

Ivabradine Aspire is taken orally as a whole tablet with or without food. The tablet should be swallowed with a glass of water and not chewed, crushed, or split unless specifically instructed by the prescriber. Dosing times are usually spaced evenly, often twice daily, as directed by the treating physician.

The most serious adverse events include symptomatic severe bradycardia (heart rate < 50 bpm), atrial fibrillation, marked hypotension, and visual disturbances such as persistent luminous phenomena or vision loss. Patients should seek immediate medical attention if they experience dizziness, fainting, palpitations, or any sudden change in vision.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), acute decompensated heart failure, and in those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with known hypersensitivity to ivabradine or any excipients.